Drugs / Prochymal®
Prochymal®
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04543994 | Nov 2020 → Nov 2023 | ulcerative colitis | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 1/2 | NCT04548583 | Nov 2020 → Nov 2023 | Crohn's colitis | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00877903 | Mar 2009 → May 2011 | myocardial infarction | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00690066 | Jun 2008 → Dec 2010 | type 1 diabetes mellitus | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00683722 | Mar 2008 → Mar 2009 | chronic bronchitis, pulmonary emphysema | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00294112 | Mar → Jul 2006 | Crohn disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00284986 | Nov 2005 → Apr 2006 | acute graft versus host disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04371393 | Apr 2020 → Jan 2021 | COVID-19, acute respiratory distress syndrome | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 3 | NCT02652130 | Oct 2015 → Jun 2018 | acute graft versus host disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02336230 | Jun 2015 → Apr 2018 | acute graft versus host disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01233960 | Nov 2010 → Sep 2014 | Crohn disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase not stated5 trials | ||||||
| — | NCT01510431 | — | Crohn disease | Mesoblast, Inc. | No longer available | No outcome recorded |
| — | NCT04366830 | — | adult acute respiratory distress syndrome | Mesoblast, Ltd. | No longer available | No outcome recorded |
| — | NCT00826046 | — | acute graft versus host disease | Mesoblast, Inc. | No longer available | No outcome recorded |
| — | NCT04456439 | — | COVID-19–associated multisystem inflammatory syndrome in children | Mesoblast, Ltd. | No longer available | No outcome recorded |
| — | NCT00759018 | — | acute graft versus host disease | Mesoblast, Inc. | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00136903 Comparator | Apr 2005 → Jul 2006 | acute graft versus host disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06893250 Comparator | Sep 2024 → Dec 2027 expected | osteoarthritis, knee | University Hospital of North Norway | Enrolling by invitation | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00562497 Comparator | Jan 2008 → Jul 2009 | acute graft versus host disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00543374 Comparator | Sep 2007 → Jul 2009 | Crohn disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00482092 Comparator | Sep 2007 → Sep 2014 | Crohn disease | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00366145 Comparator | Aug 2006 → Dec 2008 | graft versus host disease | Mesoblast, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prochymal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00482092 ↗ |
| Known as | ADSTEM Inj. | “ADSTEM Inj. (Adult human mesenchymal stem cells)” NCT06893250 ↗ |
| Known as | Adult human mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06893250 ↗ |
| Known as | remestemcel-L | “We previously reported a Phase 1/2 randomized placebo-controlled trial of systemic administration of bone marrow-derived allogeneic MSCs (remestemcel-L) in COPD.” PMID 33964910 ↗ May 2021 |
| Modality | Cell therapy | “two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®)” NCT00136903 ↗ |
| Route | Intravenous | “2 million hMSCs/kg actual body weight, IV on study Days 1 and 4” NCT00136903 ↗ |